This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/6/2026
Good morning. My name is Joanna, and I will be your conference operator today. I would like to welcome you to Canopy's second quarter 2027 financial results conference call. Currently, all participants are in a listen-only mode. I will now turn the call over to Jonathan Fink. You may begin your conference call.
Thank you, Joanna. Good morning, and thank you, everyone, for joining us. On our call today, we have Canopy Growth's Chief Executive Officer, Luc Mongeau, and Chief Financial Officer, Tom Stewart. Prior to the opening of Financial Markets today, Canopy Growth issued a news release announcing the financial results for its second quarter ended September 30, 2026. The news release and financial statements have been filed on EDGAR and CDAR and will be available on the website under the Investors tab. Before we begin, I would like to remind you that our discussion during the call will include forward-looking statements that are based on management's current views and assumptions and that this discussion is qualified in its entirety by the cautionary note regarding forward-looking statements included at the end of the news release issued today. Please review today's earnings release and Canopy's reports filed with the SEC and CDAR for various factors that could cause actual results to differ materially from projections. In addition, reconciliations between any non-GAAP measures to their closest reported gap measures are included in our earnings release. Please note that all financial information is provided in penny and dollars unless otherwise stated. Following the remarks by Luc and Tom, we will conduct a question and answer session where we will take questions from analysts. And with that, I would like to turn the call over to Luc.
Thank you, Tom. Good morning, everyone, and thank you for joining us today. Our second quarter of fiscal 2027 results show continued momentum, with another quarter of strong year-over-year top-line growth across most of the business. The consolidated net revenue increased 22% year-over-year to $81.4 million. Cannabis revenue increased by 30% to $66.2 million. Reflecting our ability to produce and supply high-quality flour to meet the demands of the Canadian and European markets. The biggest driver of growth was our international business, where net revenue increased by a tremendous 141% over June of last year, and by 28% sequentially from the first quarter to $12.3 million. International growth was enabled by strong availability of flour and a strengthened route to market that increased our reach to patients in our core European markets. Canada medical net revenue grew by 18% year-over-year to $25.8 million. Similar to last quarter, we benefited from ongoing increases in patient counts, including through the addition of the MTL Medical Biz. Our team is building from the new baseline following the VAC reimbursement cap implemented at the beginning of April, continuing to add patients, and providing best-in-class service experience for our patients. We believe our position as the number one medical cannabis provider with Canadian-owned and Canadian-grown supply will remain an important differentiator. Canada Adults Use Net Revenue increased 17% to $21.8 million. We are seeing the benefits of a strengthened product portfolio as well as the addition of MTL brands which perform well in Quebec and are building momentum in the rest of Canada. We're confident in our ability to continue to grow in this market and recently made the decision to build out an internal sales force fully dedicated to growing our brands in Canada. Our growth in cannabis revenue has been made possible by your ability to provide a more consistent supply of the right flower to consumers. Elevating cultivation has been a core focus for Canopy, with efforts accelerating since we acquired MTL Cannabis at the end of fiscal 26. We're applying the expertise of MTL's master growers to improve cultivation practices and drive increased yield and flower quality at our EUGMP facility in Kincardine. Our team has been busy implementing new growth methods and adding new strains. Early results are encouraging. We're taking steps to further increase yield and continue building on these results. We expect to see a noticeable increase in yield and flower quality as we exit the third quarter of fiscal 27 with the full impact felt in the start of fiscal 28. We believe there is a potential to increase flower production at kindergarten by at least 25 to 30 percent within the same physical footprint. We expect increased yield and quality to drive both revenue growth and per unit cost improvement. Improved cultivation is a key foundational element of our global supply chain. In addition, we are as well focusing our efforts on strengthening our global distribution and manufacturing network and improving our access to patients across Europe. On that subject, we recently received EU GMP certification at our Smith Falls facility, as well as a renewal of the EU GMP certification at Kincardine. This makes Canopy the only Canadian company with end-to-end EU GMP certification covering its entire supply chain from cultivation to the manufacturing and primary packaging of sub-gels, oils, and dry cannabis flowers. The Smith's falsification creates a path to expand into additional categories of high-quality, patient-ready products, broadening our addressable market and creating new growth opportunities. Our team is actively working with existing and new channel partners to prioritize these avenues for growth, and we expect to provide updates on this in future quarters. These capabilities are increasingly important to European customers and regulators. They enable us to maintain the highest quality standards with fewer third parties handling our products. It is clearly part of our promise of product integrity in action. Other steps we have taken to strengthen our international capabilities include relaunching the Tweed brand in Germany with FTL Cannabis Genetics, Straightening our commercial and operational leadership team in Germany to accelerate growth, broadening our product offering in Australia, and entering the UK medical cannabis market. We see international markets as a key driver of growth, and we're very excited about our prospects. Turning to stores on Bickel, we reported revenue of $15.1 million, down 4% from the second quarter of last year. Storzenbeckle is managing through ways of variability consumer spending in the face of economic uncertainties in various markets, as well as evolving trends in the space. We continue to refine our product portfolio and goods market strategies to maintain our leadership position. Storzenbeckle is known for innovation, as demonstrated by the recent recognition by Safe Access Now for recent product advancement with the Vaporization Innovation Award. Consistent with prior years, we expect a seasonally strong quartering Q3 driven by the holiday season. Overall, our financial results are showing what better execution across canopy growth can deliver. There's still a lot of work to be done, but we're sustaining our momentum in the right direction. Thank you, Luke, and good morning, everyone.
You're reading a preview of the WEED Q2 2027 earnings call.
Free account.
